BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1041 related articles for article (PubMed ID: 16498362)

  • 1. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are aromatase inhibitors superior to antiestrogens?
    Howell A; Buzdar A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatase in the context of breast and endometrial cancer. A review.
    Jongen VH; Hollema H; Van Der Zee AG; Heineman MJ
    Minerva Endocrinol; 2006 Mar; 31(1):47-60. PubMed ID: 16498363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
    Ingle JN
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are all aromatase inhibitors the same? A review of the current evidence.
    Jänicke F
    Breast; 2004 Dec; 13 Suppl 1():S10-8. PubMed ID: 15585378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
    Markopoulos C
    Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal therapy for postmenopausal breast cancer: the science of sequencing.
    Miller WR; Bartlett JM; Canney P; Verrill M
    Breast Cancer Res Treat; 2007 Jun; 103(2):149-60. PubMed ID: 17039263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
    Dixon JM
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens.
    Howell A; Dowsett M
    Breast Cancer Res; 2004; 6(6):269-74. PubMed ID: 15535858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
    Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
    Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of hormone-related cancers: breast cancer.
    Dunn BK; Wickerham DL; Ford LG
    J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
    Spicer J; Ellis P
    Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
    Poole R; Paridaens R
    Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
    Fentiman IS
    Int J Clin Pract; 2006 Jun; 60(6):689-93. PubMed ID: 16805754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addressing the future: combination with targeted therapies, adjuvant setting and beyond.
    Goss PE
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S3-5. PubMed ID: 18337641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
    Chlebowski RT
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.